• Login
    View Item 
    •   Home
    • The Manchester Institute Cancer Research UK
    • All Paterson Institute for Cancer Research
    • View Item
    •   Home
    • The Manchester Institute Cancer Research UK
    • All Paterson Institute for Cancer Research
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Herpes simplex virus VP22-human papillomavirus E2 fusion proteins produced in mammalian or bacterial cells enter mammalian cells and induce apoptotic cell death.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Roeder, Geraldine E
    Parish, Joanna L
    Stern, Peter L
    Gaston, Kevin
    Affiliation
    Department of Biochemistry, School of Medical Sciences, University of Bristol, Bristol BS8 1TD, UK.
    Issue Date
    2004-10
    
    Metadata
    Show full item record
    Abstract
    Infection by high-risk HPV (human papillomavirus) is supposed to be the primary cause of cervical cancer. The HPV E2 protein (E2) is a DNA-binding protein that regulates viral gene expression and is required for efficient viral replication. Overexpression of the E2 protein in cervical cancer cells can induce growth arrest and/or apoptotic cell death, suggesting that E2 might be useful in the treatment of this disease. In the present study, we show that VP22 (herpes simplex virus VP22 protein) can be used to deliver E2 to target cells. VP22-E2 fusion proteins induce apoptosis in transiently transfected HPV-transformed cervical carcinoma cell lines. However, VP22-E2 fusion proteins do not kill COS-7 cells, probably because these cells constitutively express the simian-virus-40 T antigen and this protein sequesters the tumour suppressor protein p53. When COS-7 cells producing VP22-E2 are seeded into cultures of HPV-transformed cells, VP22-E2 enters the non-producing cells and induces apoptosis. VP22-E2 proteins produced in bacterial cells can also enter cervical cancer cells and induce apoptosis in a dose-dependent manner. Our results suggest that local delivery of VP22-E2 fusion proteins could be used to treat cervical cancer and other HPV-associated diseases.
    Citation
    Herpes simplex virus VP22-human papillomavirus E2 fusion proteins produced in mammalian or bacterial cells enter mammalian cells and induce apoptotic cell death. 2004, 40 (Pt 2):157-65 Biotechnol. Appl. Biochem.
    Journal
    Biotechnology and Applied Biochemistry
    URI
    http://hdl.handle.net/10541/78143
    DOI
    10.1042/BA20030172
    PubMed ID
    14709162
    Type
    Article
    Language
    en
    ISSN
    0885-4513
    ae974a485f413a2113503eed53cd6c53
    10.1042/BA20030172
    Scopus Count
    Collections
    All Paterson Institute for Cancer Research

    entitlement

    Related articles

    • A cancer cell-specific inducer of apoptosis.
    • Authors: Green KL, Brown C, Roeder GE, Southgate TD, Gaston K
    • Issue date: 2007 Jun
    • VP22-mediated intercellular transport correlates with enhanced biological activity of MybEngrailed but not (HSV-I) thymidine kinase fusion proteins in primary vascular cells following non-viral transfection.
    • Authors: Sheridan PJ, Lawrie A, Crossman DC, Holt CM, Newman CM
    • Issue date: 2005 Mar
    • Diffusible VP22-E2 protein kills bystander cells and offers a route for cervical cancer gene therapy.
    • Authors: Green KL, Southgate TD, Mulryan K, Fairbairn LJ, Stern PL, Gaston K
    • Issue date: 2006 Feb
    • [Antisense targeting to human papillomavirus 18 E6/E7 affects the proliferation and apoptosis of human cervical carcinoma: an in vitro experiment with HeLa cells].
    • Authors: Sima N, Kong DB, Wang W, Lu YP, Wang SX, Ma D
    • Issue date: 2007 Jun 19
    • Poor intercellular transport and absence of enhanced antiproliferative activity after non-viral gene transfer of VP22-P53 or P53-VP22 fusions into p53 null cell lines in vitro or in vivo.
    • Authors: Zavaglia D, Lin EH, Guidetti M, Pluquet O, Hainaut P, Favrot MC, Coll JL
    • Issue date: 2005 Jul
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.